"Vaccines are proving to be far more than just shields against specific illnesses; they are emerging as powerful tools for promoting overall health, potentially reducing the risk of chronic diseases like dementia and cardiovascular conditions, and fostering a healthier aging process."
This groundbreaking insight highlights a growing body of scientific evidence suggesting that vaccinations offer a spectrum of benefits that extend beyond their primary intended purpose of preventing infectious diseases. As research advances, it is becoming increasingly clear that vaccines can have significant "indirect benefits"—positive effects on health that are not directly related to the disease the vaccine targets. These findings are reshaping our understanding of vaccine efficacy and their role in comprehensive public health strategies, particularly for aging populations.
Vaccines: A Multifaceted Shield for Aging Populations
The primary and most compelling reason for vaccination remains the direct protection against debilitating diseases. For shingles, two doses of the vaccine offer an impressive 90% defense against this painful, blistering infection caused by the varicella-zoster virus. Shingles not only causes acute discomfort but can lead to persistent nerve pain and other severe long-term complications, with one-third of Americans expected to experience it in their lifetime.
Similarly, for older adults, vaccination against the respiratory syncytial virus (RSV) is crucial. This respiratory infection, often perceived as a common cold, can lead to severe complications in seniors. Data indicates that vaccination can reduce the risk of RSV-related hospitalization by nearly 70% in the first year after immunization and by approximately 60% in the two years that follow.
The annual influenza vaccine, while varying in efficacy based on the accuracy of predicting dominant strains, reliably reduces the severity of illness, even if it doesn’t always prevent infection.
However, an expanding array of "indirect benefits" is now being uncovered, offering compelling new reasons for older adults, in particular, to embrace vaccination. These benefits, often termed "spillover effects" in medical parlance, go beyond preventing the specific illness the vaccine was designed for. The accumulation and acceleration of research in the past decade have brought these ancillary advantages to the forefront, according to Dr. William Schaffner, an infectious disease specialist at Vanderbilt University Medical Center.
While some of these protective effects have been observed for decades, others are derived from more recent studies, and their full implications are still being elucidated. The RSV vaccine, for instance, only became available in 2023, making its long-term indirect benefits a subject of ongoing investigation. Nevertheless, the findings are proving remarkably consistent, according to Dr. Stefania Maggi, a geriatrician and senior researcher at the National Research Council Neuroscience Institute in Padua, Italy.
Dr. Maggi, lead author of a significant meta-analysis published in the journal Age and Ageing, explored multiple studies and identified a reduced risk of dementia following vaccination against various diseases. She posits that these "downstream effects" underscore the role of vaccines as pivotal tools for promoting healthy aging and preventing both physical and cognitive decline.
Despite the accumulating evidence, a concerning number of older adults remain unvaccinated. This is particularly alarming given that their immune systems are naturally weaker, and the prevalence of chronic conditions increases their susceptibility to infectious diseases. As of mid-December, the Centers for Disease Control and Prevention (CDC) reported that approximately 37% of older adults had not yet received the flu vaccine. Vaccination rates for RSV were even lower, with only 42% having received it at least once. Furthermore, less than a third of this demographic had received the most recent COVID-19 vaccine.
The CDC recommends a single dose of the pneumococcal vaccine for adults aged 50 and older. However, an analysis in the American Journal of Preventive Medicine estimated that between 2022 and 2024, only 12% of individuals aged 67 to 74 and a mere 8% of those over 75 had received it, following updated recommendations.
Cardiovascular Protection and Beyond
The most robust evidence for indirect benefits, spanning over 25 years, points to a significant reduction in cardiovascular risk following influenza vaccination. Healthy older adults who receive the flu shot demonstrate a considerably lower risk of hospitalization due to heart failure, as well as pneumonia and other respiratory infections. Influenza vaccination has also been linked to a reduced risk of heart attack and stroke. Notably, many of these foundational studies were conducted before the advent of the more potent influenza vaccines now recommended for older adults, suggesting that current vaccinations may offer even greater protective effects.
The question arises: could the RSV vaccine, which targets another significant respiratory illness, confer similar cardiovascular benefits? A large-scale recent study conducted in Denmark on older adults found a nearly 10% decrease in cardiorespiratory hospitalizations (involving both the heart and lungs) among vaccinated individuals compared to a control group—a statistically significant reduction. However, the observed decrease in cardiovascular disease and stroke hospitalizations was not statistically significant. Dr. Helen Chu, an infectious disease specialist at the University of Washington and co-author of an accompanying editorial in JAMA, suggests this could be due to a short follow-up period or limitations in diagnostic testing.
"I don’t think RSV behaves very differently from influenza," Dr. Chu commented. "It’s still too early to have all the data on RSV, but I think it’s going to show the same effect, maybe even a greater one."
Vaccination against another dangerous respiratory illness, COVID-19, has also been associated with a reduced risk of developing "long COVID," a condition with debilitating physical and mental health consequences.
The Shingles Vaccine and Dementia: A Provocative Link
Perhaps the most provocative findings emerge from research on the shingles vaccine. Last year, researchers reported an association between this vaccine and lower rates of dementia, even with an older, less effective version of the vaccine that has since been replaced by Shingrix, approved in 2017.
It is important to note that most studies on indirect benefits are observational. Ethical considerations prevent researchers from withholding a safe and effective vaccine from a control group that might otherwise develop the targeted disease. This limitation means that findings could be influenced by "healthy volunteer bias," where vaccinated individuals tend to exhibit other healthy lifestyle habits that differentiate them from unvaccinated populations. While researchers strive to adjust for factors like age, sex, health status, and education level, as Dr. Maggi explained, "We can only state that there is a strong association between the vaccine and lower dementia rates, but not a causal relationship."
To address this, researchers at Stanford University utilized a natural experiment in Wales from 2013. In this scenario, the first shingles vaccine, Zostavax, was offered to individuals under the age of 80, while those who had already reached that age were ineligible. Over a seven-year period, dementia rates in the group eligible for the vaccine—even though only half actually received it—decreased by 20% compared to those who narrowly missed eligibility. "There’s no reason to think that people born a week earlier were different from those born a few days later," Dr. Maggi remarked, underscoring the potential for a causal link.
Subsequent studies in Australia and the United States have also identified a reduction in the likelihood of developing dementia following shingles vaccination. In fact, Dr. Maggi’s meta-analysis of studies revealed that several childhood and adult vaccines appear to have similar indirect effects. "We now know that many infections are associated with the development of dementia, whether it’s Alzheimer’s or vascular dementia," she stated.
Across 21 studies encompassing over 104 million participants in Europe, Asia, and North America, shingles vaccination was linked to a 24% reduction in the risk of developing dementia. For the influenza vaccine, the reduction was 13%, and for the pneumococcal vaccine, the risk of Alzheimer’s disease was 36% lower. The Tdap vaccine (tetanus, diphtheria, and acellular pertussis), recommended every 10 years for adults, was associated with a one-third decrease in dementia risk. Many individuals opt for this vaccine when a grandchild is born, as newborns cannot receive their full vaccination course in their initial months.
Further research is underway to explore whether the shingles vaccine also reduces the risk of heart attack and stroke, and whether the COVID-19 vaccine can improve survival rates for cancer patients.
The Underlying Mechanisms: Inflammation and Immunity
The prevailing hypotheses for these additional benefits center on inflammation. When the immune system is activated to combat an infection, it triggers an inflammatory response. "Damage is generated in the environment around the body’s cells, and it takes time for that to return to normal," explained Dr. Chu. The effects of inflammation can persist long after the initial illness, potentially creating an environment conducive to other infections or contributing to cardiovascular events through blood clot formation in narrowed vessels. "If you prevent the infection, you also prevent that downstream damage," Dr. Chu added.
Hospitalization itself can be a significant risk factor for dementia and other health problems, particularly for older adults who may experience loss of strength, mobility, or develop delirium during their stay. Therefore, vaccines that help prevent such hospitalizations could potentially delay or even avert cognitive deterioration.
Navigating Public Health Policy and Vaccine Hesitancy
Despite the growing body of evidence, concerning trends in vaccination rates persist. Notably, public health officials during the Trump administration publicly questioned childhood vaccines more frequently than adult ones. This open opposition may have inadvertently contributed to a broader climate of vaccine hesitancy, impacting vaccination rates among older adults. Consequently, many individuals not only miss out on the emerging indirect benefits but also remain vulnerable to preventable diseases.
"The current national policy on vaccination is, at best, ambiguous, and in some aspects seems anti-vaccine," remarked Dr. Schaffner, a former member of the CDC’s Advisory Committee on Immunization Practices. "All of us working in public health are really quite concerned." This sentiment reflects a broader anxiety within the public health community regarding the potential consequences of declining vaccination rates on both individual and societal health.